2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13B.09 Outcomes of Inpatient Chemotherapy for Patients with Newly Diagnosed Extensive Stage Small Cell Lung Cancer

EP.13B.09 Outcomes of Inpatient Chemotherapy for Patients with Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Pdf Summary

This study, presented by Sara Gauthier and colleagues, explores the outcomes of inpatient chemotherapy for patients newly diagnosed with extensive stage small cell lung cancer (ES-SCLC) at The Ottawa Hospital. Small cell lung cancer is an aggressive form of cancer, with 70% of cases diagnosed at an extensive stage. Despite the high sensitivity of SCLC to chemotherapy, few studies have focused on the outcomes of patients treated in an inpatient setting. Historically, platinum-etoposide therapy has been the standard treatment.<br /><br />The researchers conducted a retrospective review from January 2013 to December 2021, assessing overall survival (OS) as the primary endpoint. Comparisons between those who received systemic therapy and those who did not were made using the Chi-Square test, and OS was estimated with the Kaplan-Meier method.<br /><br />Out of 127 patients, 92 received systemic therapy, while 35 did not. Data indicated that median OS for those receiving therapy was 5.9 months, significantly longer than the 0.5 months for those without therapy, emphasizing the survival benefit of systemic treatment.<br /><br />The study also assessed secondary endpoints, including length of hospital stay and the incidence of tumor lysis syndrome (TLS), a life-threatening condition. About 8% of patients developed TLS, associated with liver metastases, poor performance status, and elevated lactate dehydrogenase (LDH) levels, suggesting that aggressive TLS prophylaxis might be necessary for at-risk patients.<br /><br />The findings suggest that systemic therapy prolongs life in ES-SCLC patients hospitalized compared to those who do not receive chemotherapy. Despite its retrospective design, the study highlights the need for careful monitoring and management strategies, particularly TLS risk factors, to optimize patient outcomes. The investigation also calls for further research to address potential confounding factors inherent in observational studies.

Asset Subtitle

Sara Gauthier

Meta Tag

Speaker Sara Gauthier

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

small cell lung cancer

chemotherapy outcomes

inpatient setting

systemic therapy

overall survival

tumor lysis syndrome

platinum-etoposide therapy

retrospective review

Kaplan-Meier method

liver metastases